Quick Hits

• The Fed question has fully inverted. CME FedWatch pricing — flagged in a heavily-trafficked r/investing thread — puts odds of a 25-basis-point hike at Wednesday's Sept. 16 FOMC meeting at 85%, up from 56% just two weeks ago. MarketWatch adds that economists see the Fed historically unwilling to stop at a single hike, with three increases on the table.
• Dell (DELL) and HPE (HPE) were the S&P 500's top performers Friday, after Oracle's (ORCL) earnings delivered an upbeat read on hardware demand — though MarketWatch cautions the Fed's rate path will dictate how long the halo lasts.
• Saudi Arabia temporarily shut its East-West pipeline after a drone attack, per Reuters. The line had served as a bypass around the Strait of Hormuz while Gulf shipping stays disrupted — putting the falling-oil tailwind that fueled Friday's rebound at risk.
• OpenAI's Sam Altman ruled out an IPO this year, calling this an "ill-advised" moment to go public as AI safety concerns ramp up.
• The 2027 Social Security COLA could rise another $71 a month — which MarketWatch frames as less good news than it sounds: a symptom of persistent inflation that isn't going anywhere.

Markets Overview

Friday closed with a rebound that CNBC's Jim Cramer attributed largely to falling oil prices — but he was quick to warn that next week's Federal Reserve meeting is "the next big test" for stocks. The S&P 500 has now advanced three consecutive calendar years and has pushed to record levels in 2026, per Motley Fool, though not without interruption in recent months. Heading into Monday, the weekend's Saudi pipeline shutdown clouds the one tailwind — cheaper oil — that powered Friday's bounce.

Fed & Economic Data

The two-year retail chorus of "when do the cuts start?" has flipped to pricing hikes: FedWatch odds of a September hike jumped from 56% to 85% in two weeks, and the Reddit thread that surfaced the data argues most investors are watching the wrong thing. MarketWatch's coverage of the meeting notes economists' observation that the Fed has historically not been content to raise rates only once — with a companion piece mapping where markets could face their stiffest test if the hiking cycle extends. A contrarian r/investing thread still holds out for cuts, musing about 1940s-style yield curve control to inflate the debt away — a minority view, but a reminder of how violently the consensus has shifted.

The inflation backdrop isn't cooperating either. The 2027 Social Security COLA is tracking toward another $71-per-month increase, per MarketWatch — and Motley Fool reports it's set to do something not witnessed in 30 years, a "Trump bump"-driven adjustment landing on the checks of roughly 55 million retired workers. A bigger COLA is, functionally, an inflation confession.

Earnings Reports

Oracle's earnings were the week's quietly consequential print: MarketWatch credits the results with an "upbeat read" for hardware suppliers that sent Dell and HPE to the top of the S&P 500 Friday. Further back in the tape, CRISPR Therapeutics (CRSP) zoomed nearly 19% higher in August on a solid quarterly report — a rare revenue-generating gene-editing story, per Motley Fool.

Hot Sectors

• AI hardware and networking is the trade of the moment: Dell and HPE led the index, and MarketWatch highlights a bull case on Marvell (MRVL) that extends beyond custom chips to supporting components and optical networking — an analyst-sized $30 billion opportunity in a business described as "incredibly sticky."
• Software AI monetization gets its spotlight next week: Salesforce (CRM) rides a wave of AI optimism into Dreamforce, where Wall Street wants details on how the newly announced "Claudeforce" partnership with Anthropic actually converts to revenue, per MarketWatch.
• Healthcare and defensives are drawing attention as a hedge: Motley Fool spotlights Abbott (ABT) as the Dividend King to own if a crash comes, makes the case for high-yield Medtronic (MDT), and flags Eli Lilly's (LLY) acquisition spree in the GLP-1 arena as both offense and defense of its franchise.

Stock News

• OpenAI won't IPO in 2026. Altman told MarketWatch that ramped-up AI safety concerns make going public now "ill-advised" — a notable chill on the IPO narrative even as Reddit chatter circulates about Anthropic eventually tapping public markets.
• Goldman Sachs added Vertex Pharmaceuticals (VRTX) to its conviction list, per Motley Fool, with the stock at $546 against a wide analyst target range of $350 to $672.
• Insider sales worth parsing: Quest Diagnostics (DGX) CEO J.E. Davis sold 10,000 shares at $242.72 (~$2.4 million). At Vaxcyte (PCVX), CEO Grant Pickering disposed of 6,289 shares in a tax-related transaction weeks before a Phase 3 readout, COO Jim Wassil cashed $378,000 of options struck at $5.35, and the CFO sold 2,705 shares — against a balance sheet holding $2.5 billion in cash and a $605 million half-year loss.
• Dividend declarations: Ralph Lauren (RL) at $1.00, Village Super Market (VLGEA) and Malaga Financial at $0.25 each, and Bentley Systems (BSY) at $0.07.

Market Analysis

Wednesday's FOMC decision is the whole ballgame. The 85% hike pricing means the surprise risk is less about the move itself than the path — if the MarketWatch economists' three-hike scenario gains traction, rate-sensitive trades like the Dell/HPE hardware rally face their stiffest test, exactly as MarketWatch warned. Layered on top: whether oil's Friday slide reverses after the Saudi pipeline shutdown, and whether Dreamforce delivers concrete evidence that AI software revenue — Claudeforce included — is catching up to the hardware boom. Cramer's framing is the right one: falling oil helped, but the Fed decides what happens next.